Singapore markets open in 22 minutes

Straits Times Index
3,410.81
-29.07(-0.85%)
S&P 500
5,567.19
+30.17(+0.54%)
Dow
39,375.87
+67.87(+0.17%)
Nasdaq
18,352.76
+164.46(+0.90%)
Bitcoin USD
55,786.80
-2,291.03(-3.94%)
CMC Crypto 200
1,158.32
-50.37(-4.17%)

HRTX Sep 2024 1.500 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.0400

0.0000

(0.00%)

As of 12:09PM EDT. Market open.

Zacks
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
PR Newswire
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.
Simply Wall St.
With 55% ownership of the shares, Heron Therapeutics, Inc. (NASDAQ:HRTX) is heavily dominated by institutional owners
Key Insights Significantly high institutional ownership implies Heron Therapeutics' stock price is sensitive to their...